Long term follow up of an Alemtuzumab (CAMPATH-1H) containing reduced intensity Allogeneic Transplant Regimen for Non-Hodgkins Lymphoma (NHL)

Reviewer: Julie Draznin Maltzman, MD
OncoLink
Ultima Vez Modificado: 8 de diciembre del 2002

Translation for this article does not exist

Blogs

The Power of a Cancer Support Group
by Bob Riter
May 26, 2016